Acute Blood Pressure Management in ICH
Blood pressure (BP) management is the most extensively studied acute intervention in intracerebral hemorrhage (ICH). The rationale is straightforward: elevated systolic blood pressure (SBP) drives hematoma expansion (HE), which occurs in roughly one-third of patients within 6 hours and is the strongest modifiable predictor of poor outcome. Five major randomized trials — from INTERACT2 through INTERACT4 — have progressively refined our understanding of optimal targets, timing, and the limits of aggressive lowering.
🔹 Bottom Line: BP Management in ICH
- Target SBP 130–150 mmHg in mild-to-moderate ICH with presenting SBP 150–220 mmHg (AHA Class 2b). Initiate within 2 hours, achieve target within 1 hour.
- Avoid SBP <130 mmHg — ATACH-2 showed increased renal adverse events without functional benefit (Class 3: Harm).
- Earlier is better: INTERACT4 (2024) showed that ambulance-initiated BP lowering significantly improved outcomes in ICH patients (cOR 0.75), reduced HE, and improved survival — but harmed ischemic stroke patients.
- Bundle approach works: INTERACT3 embedded BP control within a protocolized care bundle and became the first positive acute ICH trial (OR 0.86, NNT ~35).
- BP variability is harmful: Smooth, sustained reduction is critical — avoid peaks and troughs (AHA Class 2a).
1. Rationale: Blood Pressure & Hematoma Expansion
Hematoma expansion is the principal mechanism by which elevated BP worsens ICH outcomes. Approximately 73% of expansion occurs within the first 6 hours, with the majority in the first 3 hours. Elevated SBP accelerates ongoing bleeding from ruptured small arteries and arterioles, and the relationship between SBP reduction and HE attenuation has been demonstrated across multiple trials.
The concept is often compared to "reducing water flow through a tap" — BP reduction decreases but does not fully eliminate the risk of HE. The CTA "spot sign" (active contrast extravasation) identifies patients at highest HE risk, though BP lowering benefits appear to extend across the entire ICH population regardless of spot sign status.
Importantly, perihematomal ischemia — once a major concern with aggressive BP lowering — has been shown by perfusion imaging studies to be uncommon and generally not clinically significant, providing the physiological rationale for more intensive treatment.
2. INTERACT2: Defining the Target
INTERACT2 (2013) was the first large RCT to establish an intensive BP target in acute ICH. The trial enrolled 2,839 patients within 6 hours of ICH onset with SBP 150–220 mmHg, randomizing them to intensive (<140 mmHg within 1 hour) or guideline-recommended (<180 mmHg) management.
The primary endpoint — death or major disability (mRS 3–6) at 90 days — did not reach statistical significance (52.0% vs. 55.6%; OR 0.87; 95% CI 0.75–1.01; p=0.06). However, a pre-specified ordinal mRS shift analysis showed significant benefit favoring intensive treatment (OR 0.87; p=0.04), and intensive BP lowering significantly improved health-related quality of life (EQ-5D). There was no increase in serious adverse events.
INTERACT2 established SBP <140 mmHg as a reasonable target but left uncertainty about how aggressively to pursue it — a question that ATACH-2 would attempt to answer.
3. ATACH-2: The Limits of Aggressive Lowering
ATACH-2 (2016) tested whether more aggressive SBP lowering (110–139 mmHg) was superior to standard reduction (140–179 mmHg). The trial enrolled 1,000 patients within 4.5 hours of onset using exclusively IV nicardipine and was stopped early for futility.
The primary outcome — death or disability (mRS 4–6) at 3 months — was identical between groups (38.7% intensive vs. 37.7% standard; RR 1.04; 95% CI 0.85–1.27). Critically, patients in the intensive arm experienced significantly more renal adverse events within 7 days (9.0% vs. 4.0%; p=0.002), directly attributable to lowering SBP below 130 mmHg.
🔴 Avoid SBP <130 mmHg in Acute ICH
- ATACH-2 demonstrated that SBP reduction to <130 mmHg was associated with renal adverse events and no functional benefit.
- A pooled individual patient data analysis of INTERACT2 + ATACH-2 (Wang et al., 2022) confirmed a J-shaped relationship: both high (>160 mmHg) and low (<120 mmHg) achieved SBP were associated with worse outcomes.
- The optimal achieved SBP range is 130–150 mmHg — aggressive enough to limit HE, not so aggressive as to cause ischemic organ injury.
4. INTERACT3: BP Within a Care Bundle
INTERACT3 (2023) shifted the paradigm by embedding BP control within a protocolized care bundle. This stepped-wedge cluster RCT across 121 hospitals in 10 countries enrolled 7,036 patients and implemented a goal-directed bundle targeting:
- SBP <140 mmHg within 1 hour
- Glucose control (6.1–7.8 mmol/L in non-diabetics; 7.8–10.0 mmol/L in diabetics)
- Antipyrexia (temperature ≤37.5°C)
- Rapid INR reversal (<1.5 within 1 hour in anticoagulated patients)
The primary endpoint — ordinal mRS at 6 months — showed significant improvement with the care bundle (OR 0.86; 95% CI 0.76–0.97; p=0.015). Mortality was also reduced (13.6% vs. 16.6%; OR 0.77; p=0.015; NNT = 35), and there were fewer serious adverse events in the bundle group. This made INTERACT3 the first positive phase 3 RCT in acute ICH treatment.
🔹 Clinical Relevance: The Care Bundle Approach
- INTERACT3's positive result may reflect the synergy of multiple interventions rather than BP lowering alone. The bundled approach ensures that ICH patients receive all evidence-based interventions simultaneously.
- The NNT of ~35 means treating 35 patients with the care bundle prevents 1 death — a clinically meaningful effect.
- Implementation requires protocolized order sets, nursing-driven protocols, and systems-level quality improvement — not just physician awareness.
5. INTERACT4: The Prehospital Frontier
INTERACT4 (2024) tested the hypothesis that ultra-early, ambulance-initiated BP lowering could further improve ICH outcomes. This PROBE trial in China randomized 2,404 patients with suspected acute stroke and SBP ≥150 mmHg within 2 hours of symptom onset to immediate IV urapidil (target SBP 130–140 mmHg) or usual care.
The overall trial was neutral — the primary outcome of ordinal mRS at 90 days showed no difference (cOR 1.00; 95% CI 0.87–1.15). This was because the cohort was mixed: 46.5% had hemorrhagic stroke and 53.5% had ischemic stroke, with divergent treatment effects by stroke type.
ICH Subgroup: Significant Benefit
In patients with hemorrhagic stroke, ambulance-initiated BP lowering produced substantial benefits across multiple endpoints:
- Functional outcome: Significant mRS improvement (cOR 0.75; 95% CI 0.60–0.92)
- Mortality: Reduced from 31% to 24%
- Hematoma expansion: Relative growth at 24h reduced (15% vs. 21%)
- Quality of life: Improved EQ-5D scores
- Complications: Fewer serious adverse events (27% vs. 34%), reduced need for surgery and lower infection rates
Ischemic Stroke Subgroup: Signal of Harm
In ischemic stroke patients, ambulance-initiated BP lowering was associated with worse functional outcomes. This divergent effect explains the neutral overall result and highlights the critical importance of early stroke subtype diagnosis before initiating aggressive BP treatment.
🔹 Clinical Relevance: Prehospital BP Lowering
- INTERACT4 provides the strongest evidence yet that time-to-treatment matters in ICH BP management — ambulance initiation was substantially earlier than any prior trial.
- The challenge: prehospital BP lowering requires knowing the stroke subtype, which is impossible without neuroimaging.
- Mobile stroke units (MSUs) with CT capability could enable this, but are costly and limited in availability. Portable brain scanners using advanced technologies are under development.
- For now, the pragmatic approach is rapid emergency department diagnosis followed by immediate BP treatment in confirmed ICH — every minute counts.
6. Guideline Recommendations
| Recommendation | AHA 2022 COR/LOE |
ESO 2025 |
|---|---|---|
| Initiate treatment within 2 hours of onset, achieve target within 1 hour | 2a / C-LD | Weak For |
| SBP 150–220 mmHg → target 140 mmHg, maintain 130–150 mmHg | 2b / B-R | Weak For |
| Smooth, sustained BP control — avoid variability | 2a / B-NR | — |
| SBP >220 mmHg → aggressive reduction with IV infusion | 2b / C-LD | Consensus |
| Large/severe ICH or surgical candidates → safety not well established | 2b / C-LD | — |
| SBP lowering to <130 mmHg → potentially harmful | 3: Harm / B-R | Weak Against |
Practical BP Protocol
| Presenting SBP | Agents | Target | Monitoring |
|---|---|---|---|
| 150–220 mmHg | IV nicardipine, labetalol, or clevidipine | 130–150 mmHg within 1 hour | Q5 min until stable → Q15 min × 2h → Q30 min × 6h → hourly |
| >220 mmHg | IV nicardipine or clevidipine infusion | Gradual reduction to 130–150 mmHg | Continuous arterial line monitoring recommended |
| <150 mmHg | Typically no acute intervention needed | Maintain without further reduction | Standard neurological checks |
7. Knowledge Gaps & Ongoing Research
- Subtype-specific targets: Optimal BP targets may differ between deep hypertensive ICH and lobar CAA-related ICH — no trial has stratified by etiology.
- Large/severe ICH: Both INTERACT2 and ATACH-2 excluded patients with GCS <5 or imminent need for surgery. Evidence for BP targets in the most severe ICH remains sparse.
- Prehospital differentiation: INTERACT4 underscores the need for rapid stroke subtype diagnosis. Portable brain scanners and biomarkers (e.g., GFAP) are under investigation.
- Combined strategies: The TIME-ICH trial (NCT06760078) will test tranexamic acid + intensive BP lowering as a combined ultra-early strategy.
- Duration of treatment: Optimal duration of acute BP lowering (24h vs. 72h vs. 7 days) and transition to oral agents remain undefined.
8. Trial Comparison Table
| Trial | Year | N | Window | Intervention | Control | Primary Outcome | Key Finding |
|---|---|---|---|---|---|---|---|
| INTERACT Pilot | 2008 | 404 | 6h | SBP <140 | SBP <180 | HE at 24h | Trend to reduced HE (absolute difference 1.7 mL, p=0.04 by ANCOVA); feasibility confirmed |
| INTERACT2 | 2013 | 2,839 | 6h | SBP <140 | SBP <180 | mRS 3–6 at 90d | Primary endpoint neutral (OR 0.87, p=0.06); ordinal shift significant (p=0.04) |
| ATACH-2 | 2016 | 1,000 | 4.5h | SBP 110–139 | SBP 140–179 | mRS 4–6 at 3mo | Neutral (RR 1.04); ↑renal AEs with SBP <130 (9% vs 4%, p=0.002) |
| INTERACT3 | 2023 | 7,036 | — | Care bundle (SBP <140 + glucose + temp + INR) | Usual care | Ordinal mRS at 6mo | Positive (OR 0.86, p=0.015); mortality reduced (OR 0.77, NNT ~35) |
| INTERACT4 | 2024 | 2,404 | 2h (ambulance) | SBP 130–140 (IV urapidil in ambulance) | Usual care | Ordinal mRS at 90d | Overall neutral; ICH subgroup: significant benefit (cOR 0.75); ischemic stroke subgroup: harm |
References
- Anderson CS, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage (INTERACT Pilot). Lancet Neurol. 2008;7(5):391–399.
- Anderson CS, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355–2365.
- Qureshi AI, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375(11):1033–1043.
- Ma L, et al. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3). Lancet. 2023;402(10395):27–40.
- Li G, et al. Intensive ambulance-delivered blood-pressure reduction in hyperacute stroke. N Engl J Med. 2024;390(20):1862–1872.
- Wang X, et al. J-shape relation of blood pressure reduction and outcome in acute intracerebral hemorrhage: A pooled analysis of INTERACT2 and ATACH-II. Int J Stroke. 2022;17(10):1129–1136.
- Greenberg SM, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage. Stroke. 2022;53(7):e282–e361.
- Steiner T, et al. European Stroke Organisation (ESO) guideline on stroke due to spontaneous intracerebral haemorrhage. Eur Stroke J. 2025.